SCHEMBL4136016

SCHEMBL4136016

Cc1cc(C)cc(-c2ccc3c(c2)CCC(N2CCCC2)C3)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 2/20 0.41
GRIN2B Q13224 2/20 0.40
LMNA P02545 1/20 0.38
HTR1A P08908 1/20 0.38
HTR7 P34969 1/20 0.38
FAAH O00519 1/20 0.37
FYN P06241 1/20 0.36
EBP Q15125 1/20 0.35
DHCR7 Q9UBM7 1/20 0.35
OPRM1 P35372 2/20 0.34
OPRK1 P41145 2/20 0.34
OPRL1 P41146 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP11B1 P15538 2/20 0.34
CYP11B2 P19099 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2B6 P20813 1/20 0.34
OPRD1 P41143 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4136458 0.89 HRH3 (0.45) HTR1DGRIN2BLMNAHTR1AHTR7
SCHEMBL4137087 0.86 HTR1D (0.41) HTR1DGRIN2BLMNAHTR1AHTR7
SCHEMBL13102476 0.84 LMNA (0.47) HTR1DGRIN2BLMNAHTR1AHTR7
SCHEMBL4149129 0.83 HTR1D (0.38) HTR1DGRIN2BHTR1AHTR7FAAH
SCHEMBL4145248 0.83 GRIN2B (0.51) HTR1DGRIN2BHTR1AHTR7FAAH
SCHEMBL4133407 0.83 HTR1A (0.43) HTR1DGRIN2BLMNAHTR1AHTR7
SCHEMBL4148545 0.82 HTR1A (0.44) HTR1DGRIN2BHTR1AHTR7FAAH
SCHEMBL4141143 0.82 OPRM1 (0.44) HTR1DGRIN2BHTR1AHTR7FAAH
SCHEMBL4147479 0.82 FYN (0.44) HTR1DGRIN2BHTR1AHTR7FAAH
SCHEMBL4132535 0.82 OPRM1 (0.44) HTR1DGRIN2BHTR1AHTR7FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR MCHARDY STANTON FURST 2009-06-25 US claimed
EP-2007749-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR Pfizer Products Inc. (US) 2008-12-31 EP claimed
WO-2007105053-A2 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR PFIZER PRODUCTS INC. (US) 2007-09-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163482-A1 TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR HRH3, HRH4, HRH1 HTR1D 25/4885GRIN2B 86/4885LMNA 4576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.